Sort
23,748 grants matching “melanoma”
Roles of CD47 Signaling in Tumor Immunology
$107,268David D Roberts · Division Of Clinical Sciences - Nci · ZIA · FY2024 · CA
Metabolic Engineering of Cancer for Immunotargeting
$107,100Case Western Reserve University · R01 · FY2005 · CA
Targeting Endogenous Retrovirus Regulation for Augmenting Cancer Immunotherapy
$107,050Meaghan K. McGeary · Massachusetts Institute Of Technology · K00 · FY2025 · CA
Targeting Endogenous Retrovirus Regulation for Augmenting Cancer Immunotherapy
$107,050Meaghan K. McGeary · Massachusetts Institute Of Technology · K00 · FY2024 · CA
PARP Inhibitors for Chemotherapy of Brain Tumors
$107,000Guilford Pharmaceuticals, Inc. · R43 · FY2004 · CA
ALTERATIONS IN THE PITSLRE PROTEIN KINASE IN MELANOMA
$106,923University Of Arizona · R29 · FY2000 · CA
Utah Population Database Shared Resource
$106,860Geraldine P Mineau · University Of Utah · P30 · FY2012 · CA
Patterns of Care (POC) Quality of Care Dx Yr 2011
$106,858Thomas Tucker · University Of Kentucky · N01 · FY2012 · CA
HDR Brachytherapy for Intraocular Melanoma
$106,801John J Munro · Source Production And Equipment Company · R43 · FY2008 · CA
A MODEL FOR GENETIC SUSCEPTIBILITY: MELANOMA
$106,737Sloan-Kettering Institute For Cancer Res · U01 · FY2003 · CA
Prognostic markers in metastatic melanoma
$106,666Bonnie Elyssa Gould Rothberg · Yale University · K08 · FY2010 · CA
CORE--MICROSCOPIC IMAGING
$106,643W Matthew Petroll · Ut Southwestern Medical Center · R24 · FY2006 · EY
The Use of Novel Implantable Cancer Vaccines for the Treatment of Oral Cancer
$106,634Simon Young · Harvard Medical School · K99 · FY2014 · DE
The Use of Novel Implantable Cancer Vaccines for the Treatment of Oral Cancer
$106,634Simon Young · Harvard Medical School · K99 · FY2013 · DE
Basic-Optical Biology Core (OBC)
$106,607J Lawrence Marsh · University Of California-Irvine · P30 · FY2016 · CA
PHASE II EVALUATION OF IV MELPHALAN (L PAM) AND WBH FOR MALIGNANT MELANOMA
$106,600University Of Wisconsin Madison · M01 · FY2002 · RR
PHASE I/IB TRIAL OF HU14 18 IL 2 FUSION PROTEIN IN PATIENTS W/ GD2+ T
$106,600University Of Wisconsin Madison · M01 · FY2002 · RR
PHASE II EVALUATION OF IV MELPHALAN (L PAM) AND WBH FOR MALIGNANT MELANOMA
$106,600University Of Wisconsin Madison · M01 · FY2001 · RR
PHASE II STUDY OF L PAM PLUS BSO IN PATIENTS W/ METASTATIC MELANOMA
$106,600University Of Wisconsin Madison · M01 · FY2002 · RR
IMMUNIZATION WITH AUTOLOGOUS TUMOR CELLS TRANSFECTED WITH GM-CSF GENE BY PMT
$106,600University Of Wisconsin Madison · M01 · FY2001 · RR
IMMUNIZATION WITH AUTOLOGOUS TUMOR CELLS TRANSFECTED WITH GM-CSF GENE BY PMT
$106,600University Of Wisconsin Madison · M01 · FY2002 · RR
PHASE II STUDY OF L PAM PLUS BSO IN PATIENTS W/ METASTATIC MELANOMA
$106,600University Of Wisconsin Madison · M01 · FY2001 · RR
PHASE I/IB TRIAL OF HU14 18 IL 2 FUSION PROTEIN IN PATIENTS W/ GD2+ T
$106,600University Of Wisconsin Madison · M01 · FY2001 · RR
Engineered microtumor arrays for development of combination therapies
$106,589Kristopher Alan Kilian · University Of New South Wales · R01 · FY2024 · CA
Humanization of a mouse anti-OX40 monoclonal antibody to treat cancer
$106,505Dennis Triglia · Agonox, Inc. · R43 · FY2014 · CA